bluebird bio Inc (NAS:BLUE)
$ 0.9624 0.06 (6.64%) Market Cap: 185.50 Mil Enterprise Value: 303.88 Mil PE Ratio: 0 PB Ratio: 0.46 GF Score: 25/100

bluebird bio Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 15, 2022 / 11:00PM GMT
Release Date Price: $3.48 (-2.79%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good afternoon. Thanks, everyone, for joining us. We're really pleased to have the bluebird bio team with us. We have Andrew Obenshain, CEO; Tom Klima, Chief Commercial Officer; and Jason Cole, Chief Strategy and Financial Officer.

And with that, Andrew, I'm going to turn it over to you, but big congratulations for the double unanimous FDA panel last week.

Andrew Obenshain
bluebird bio, Inc. - President, CEO & Director

Yes. Thank you very much, Salveen. I think it's -- this was a -- it was a tremendous moment for bluebird, but really it was just a tremendous moment for the industry as well because I think it had a lot of read-through to gene therapy in general.

But specifically for bluebird, for us, it was -- it really had a number of knock-on effects, super positive other than celebrations in the office. We were talking now that we're -- have a high degree of confidence that when our PDUFA dates come in August and September, that we'll get approval. And with that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot